Form 4: Replimune Group Director Acquires Stock Options
SEC Form 4 Filing
Joseph P. Slattery, a director of Replimune Group, Inc., acquired stock options for 32,000 shares on April 1, 2025.
Summary
- On April 1, 2025, Joseph P. Slattery, a director of Replimune Group, Inc., acquired stock options.
- The stock options grant the right to buy 32,000 shares of common stock at an exercise price of $8.40.
- The options vest entirely on April 1, 2026, and expire on April 1, 2035.
- Following the transaction, Mr. Slattery directly owns derivative securities for 32,000 shares.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reporting a standard transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the trading activities of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could be perceived positively by shareholders as it aligns the director's interests with the company's long-term success.
Key Dates
| Date | Description |
|---|---|
| 04/01/2025 | Date of transaction: Joseph P. Slattery acquired stock options. |
| 04/01/2026 | Vesting date for the stock options. |
| 04/01/2035 | Expiration date for the stock options. |
| 04/03/2025 | Date of signature on the Form 4 filing. |
Keywords
Replimune Group, stock options, Form 4, director, acquisition, beneficial ownership, securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.